StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research note issued to investors on Thursday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35. The firm has a market cap of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a one year low of $0.00 and a one year high of $0.00.
Genocea Biosciences Company Profile
Further Reading
- Five stocks we like better than Genocea Biosciences
- What Investors Need to Know to Beat the Market
- Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
- Stock Market Sectors: What Are They and How Many Are There?
- Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
